Literature DB >> 25056363

Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.

James W Keck1, Lisa R Bulkow2, Gregory A Raczniak3, Susan E Negus4, Carolyn L Zanis2, Michael G Bruce2, Philip R Spradling5, Eyasu H Teshale5, Brian J McMahon6.   

Abstract

Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25056363      PMCID： PMC4178570          DOI： 10.1128/CVI.00263-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  12 in total

1.  Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.

Authors:  Tanja Bauer; Wolfgang Jilg
Journal:  Vaccine       Date:  2005-09-01       Impact factor: 3.641

Review 2.  Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.

Authors: 
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

3.  CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management.

Authors:  Sarah Schillie; Trudy V Murphy; Mark Sawyer; Kathleen Ly; Elizabeth Hughes; Ruth Jiles; Marie A de Perio; Meredith Reilly; Kathy Byrd; John W Ward
Journal:  MMWR Recomm Rep       Date:  2013-12-20

4.  Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program.

Authors:  R Harpaz; B J McMahon; H S Margolis; C N Shapiro; D Havron; G Carpenter; L R Bulkow; R B Wainwright
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

Review 5.  Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.

Authors:  J Banatvala; P Van Damme; S Oehen
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

6.  Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers.

Authors:  J L Williams; C J Christensen; B J McMahon; L R Bulkow; H H Cagle; J S Mayers; C L Zanis; A J Parkinson; H S Margolis
Journal:  Vaccine       Date:  2001-07-16       Impact factor: 3.641

7.  Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy.

Authors:  Paolo Bonanni; Giovanna Pesavento; Angela Bechini; Emilia Tiscione; Francesco Mannelli; Cristiana Benucci; Antonella Lo Nostro
Journal:  Vaccine       Date:  2003-01-30       Impact factor: 3.641

8.  Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report.

Authors:  David Yiu-Kuen But; Ching-Lung Lai; Wei-Ling Lim; James Fung; Danny Ka-Ho Wong; Man-Fung Yuen
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

9.  Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.

Authors:  Taraz Samandari; Anthony E Fiore; Susan Negus; James L Williams; Wendi Kuhnert; Brian J McMahon; Beth P Bell
Journal:  Pediatrics       Date:  2007-07-16       Impact factor: 7.124

10.  Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence.

Authors:  Marianne A B van der Sande; Pauline A Waight; Maimuna Mendy; Syed Zaman; Steve Kaye; Omar Sam; Abi Kahn; David Jeffries; Aveika A Akum; Andrew J Hall; Ebrima Bah; Samuel J McConkey; Pierre Hainaut; Hilton C Whittle
Journal:  PLoS One       Date:  2007-08-15       Impact factor: 3.240
View more
  6 in total

1.  Comparison of the effect of increased hepatitis B vaccine dosage on immunogenicity in healthy children and adults.

Authors:  Guodong Kang; Haiping Chen; Fubao Ma; Yunkai Yang; Zhiguo Wang; Shaohong Guo; Jiping Song
Journal:  Hum Vaccin Immunother       Date:  2016-05-23       Impact factor: 3.452

2.  Factors influencing immunologic response to hepatitis B vaccine in adults.

Authors:  Shigui Yang; Guo Tian; Yuanxia Cui; Cheng Ding; Min Deng; Chengbo Yu; Kaijin Xu; Jingjing Ren; Jun Yao; Yiping Li; Qing Cao; Ping Chen; Tiansheng Xie; Chencheng Wang; Bing Wang; Chen Mao; Bing Ruan; Tian'an Jiang; Lanjuan Li
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

3.  Evaluation of response to hepatitis B vaccine in Iranian 6-18-year-old students.

Authors:  Alizamen Salehifard Jouneghani; Morteza Hashemzadeh Chaleshtori; Abolfazl Khoshdel; Soleiman Kheiri; Effat Farrokhi; Pooran Khalafian; Zahra Aliyari
Journal:  J Res Med Sci       Date:  2017-10-31       Impact factor: 1.852

4.  Immune Persistence After Infant Hepatitis-B Vaccination: A Systematic Review and Meta-Analysis.

Authors:  Sajid Mahmood; Kifayat Ullah Shah; Tahir Mehmood Khan
Journal:  Sci Rep       Date:  2018-08-22       Impact factor: 4.379

Review 5.  Hepatitis Vaccines.

Authors:  Sina Ogholikhan; Kathleen B Schwarz
Journal:  Vaccines (Basel)       Date:  2016-03-11

6.  Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda.

Authors:  Moses Ocan; Frances Acheng; Carol Otike; Judith Beinomugisha; David Katete; Celestino Obua
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.